Scinai Immunotherapeutics has concluded its option and license agreements with PinCell for the PC111 program, choosing not to pursue further funding or extension. The company will now focus its resources on advancing its NanoAb platform and expanding its contract development and manufacturing organization (CDMO) business. This strategic shift aims to optimize capital allocation by prioritizing programs with secured funding and commercial potential, including ongoing collaborations with the Max Planck Society and University Medical Center Göttingen. Scinai also reported growing CDMO orders and is working on a significant U.S. clinical manufacturing project, positioning the company for sustainable growth and shareholder value creation.
Opus Genetics, a clinical-stage biotech focused on inherited retinal diseases, received a Buy rating and $8 price target from analyst Matthew Caufield in August 2026. The company plans to release topline Phase 1/2 data for its gene therapy OPGx-BEST1...
General Electric (GE) announced it will acquire Consolidated Precision Products (CPP) for $11.75 billion to enhance its aerospace casting production. This strategic move aims to strengthen GE's manufacturing capabilities and accelerate engine technol...
United Natural Foods, Inc. (UNFI) reported a Q4 adjusted EPS of $0.69, surpassing analyst expectations of $0.61, signaling strong profitability. However, revenue slightly missed estimates at $7.64 billion, down 0.7% from the previous year. Despite th...
Ionis Pharmaceuticals faced a setback when its experimental heart drug pelacarsen failed a Phase 3 trial to reduce cardiovascular events, causing an 8.6% stock drop. However, an analyst from Canaccord Genuity maintained a bullish $85 price target, im...
Casey's General Stores will release its Q3 2026 earnings on September 8 after market close, with analysts expecting an EPS of $6.78 and revenue of $5.56 billion. The company has a strong history of exceeding earnings estimates, with an average surpri...
